{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"129","upperLimit":"140","value":"133"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.\n\nConcurrent therapeutic medications:\n\n* Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14\n* Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)\n\nOther drugs:\n\n* Aspirin: 81 or 325 mg daily oral\n* Pegfilgrastim subcutaneous on Day 2\n\nAmrubicin: 40, 60, or 80 mg/m2 intravenous (IV)\n\nLenalidomide: 15 mg daily by mouth\n\nDexamethasone: 40 mg weekly by mouth\n\nAspirin: 81 or 325 mg daily by mouth\n\nPegfilgrastim: 6 mg subcutaneous on Day 2","id":"OG000","title":"Amrubicin + Lenalidomide + Dexamethasone"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"140 days","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"days"}